Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Dilated Cardiomyopathy Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.
The global dilated cardiomyopathy (DCM) market is expected to grow substantially due to increasing prevalence, advancements in diagnostic technologies, and the development of novel therapeutic options. The rising burden of heart failure, aging populations, and increasing awareness about cardiovascular diseases are key drivers of this growth.
The rising prevalence of cardiovascular diseases is a major driver of the dilated cardiomyopathy (DCM) market. Conditions such as heart failure, obesity, hypertension, and diabetes are on the rise globally, significantly contributing to the increasing incidence of DCM. According to the World Health Organization, heart disease remains the leading cause of death worldwide, with DCM comprising a substantial portion of heart failure cases. This growing burden is fueling demand for effective diagnostic and therapeutic solutions.
Moreover, advances in diagnostic technologies, including echocardiography, cardiac MRI, and genetic testing, are improving the early detection and diagnosis of DCM, enabling timely intervention and better disease management. Additionally, the development of targeted therapies based on genetic insights and personalized medicine is opening new avenues for treatment. Drugs such as beta-blockers, ACE inhibitors, ARBs, and anticoagulants are gaining traction, especially as they address the underlying mechanisms of heart failure.
Despite ongoing advancements, the dilated cardiomyopathy (DCM) market faces several key restraints that limit its growth potential. One of the primary challenges is the limited availability of effective treatment options for advanced-stage DCM. While medications such as ACE inhibitors and beta-blockers can help manage symptoms and slow disease progression in earlier stages, treatment options for severe cases remain scarce. Heart transplantation is often the only viable solution for advanced DCM, but donor availability is low, and the procedure is costly and associated with significant medical risks.
The high cost of emerging therapies including gene therapies, biologics, and transplant procedures further restricts access, particularly in low- and middle-income regions. Moreover, the expense and complexity of genetic testing for identifying familial forms of DCM create additional barriers, especially for uninsured or underinsured patients. The absence of standardized treatment protocols also complicates clinical decision-making, making it difficult for healthcare providers to consistently deliver optimal care. Additionally, current medications can produce adverse effects such as kidney dysfunction, electrolyte imbalances, and fatigue, which pose ongoing challenges in patient management and adherence. These factors collectively hinder the broader adoption and accessibility of DCM treatments.
Key Topics Covered
1. Markets Overview
1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Pricing Analysis
1.5 Pipeline Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities
2. Global Dilated Cardiomyopathy Market (Region), ($Million), 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Dilated Cardiomyopathy Market, by Country
2.1.3.1.1 U.S.
2.1.3.1.2 Canada
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Dilated Cardiomyopathy Market, by Country
2.2.3.1.1 Germany
2.2.3.1.2 U.K.
2.2.3.1.3 France
2.2.3.1.4 Italy
2.2.3.1.5 Spain
2.2.3.1.6 Rest-of-Europe
2.3 Asia Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia Pacific Dilated Cardiomyopathy Market, by Country
2.3.3.1.1 China
2.3.3.1.2 Japan
2.3.3.1.3 India
2.3.3.1.4 South Korea
2.3.3.1.5 Australia
2.3.3.1.6 Rest-of- Asia Pacific
2.4 Rest-of-the-World
2.4.1 Key Findings
2.4.2 Market Dynamics
2.4.3 Market Sizing and Forecast
3. Global Dilated Cardiomyopathy Market: Competitive Landscape and Company Profiles
3.1 Key Developments
3.1.1 Mergers and Acquisitions
3.1.2 Synergistic Activities
3.1.3 Business Expansions and Funding
3.1.4 Product Launches and Approvals
3.1.5 Other Activities
3.2 Company Profiles
3.2.1 Bristol Myers Squibb
3.2.2 Cumberland Pharmaceuticals
3.2.3 Berlin Cures
3.2.4 AstraZeneca
3.2.5 Rocket Pharmaceuticals, Inc. (Renovacor)
3.2.6 Tenaya Therapeutics
4. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/ke6hn5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
